Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

Higashide, Tomomi; Murotani, Eiji; Saito, Yoshiaki; Ohkubo, Shinji; Sugiyama, Kazuhisa
April 2012
Graefe's Archive of Clinical & Experimental Ophthalmology;Apr2012, Vol. 250 Issue 4, p603
Academic Journal
Background: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been reported to cause rapid regression of anterior segment neovascularization in eyes with neovascular glaucoma when administered intraocularly. Several studies have reported the safety profile of intravitreal injections of bevacizumab in patients with various retinal pathologies. We investigated the occurrence of adverse events associated with intraocular bevacizumab injections in patients with neovascular glaucoma. Methods: We retrospectively reviewed the charts of 84 eyes of 70 patients with neovascular glaucoma that received intraocular bevacizumab injections to treat anterior segment neovascularization for the first time at Kanazawa University Hospital. Results: The mean age of the patients was 63.5 ± 13.3 years (± standard deviation; range, 31-85 years). The underlying retinal diseases were proliferative diabetic retinopathy in 58 eyes (69%), central retinal vein occlusion in 17 eyes (20%), ocular ischemic syndrome in four eyes (5%), central retinal artery occlusion in three eyes (4%), branch retinal vein occlusion in one eye (1%), and radiation retinopathy in one eye (1%). The total number of intraocular injections of bevacizumab was 116 (1.4 ± 0.8 injections/eye, range, one to five injections/eye). Most were intravitreal injections (1.25 mg/0.05 ml; 115 injections, 99%). No cases had marked inflammation, lens injuries, marked vitreous hemorrhage, retinal detachment, or endophthalmitis. However, two eyes (2%) of two cases (3%) developed central retinal artery occlusion 3 or 4 days after bevacizumab injection. Both were among four eyes (i.e., 50%) with ocular ischemic syndrome. One of them had received an intracameral injection of bevacizumab (0.75 mg/0.03 ml) before the adverse event. No cases experienced systemic side-effects including myocardial infarction and cerebrovascular accidents within 3 months after bevacizumab injection. Conclusions: Central retinal artery occlusion may be a relatively common complication following intraocular injection of anti-VEGF agents in patients with neovascular glaucoma, particularly when it was associated with ocular ischemic syndrome. Since visual prognosis of central retinal artery occlusions is usually poor, intraocular injection of anti-VEGF agents should be performed with thoughtful consideration of the risks and benefits of the treatment, and with a strict follow-up examination, especially in high-risk patients.


Related Articles

  • LUCENTIS VS AVASTIN: NEEDS MUST OR DEVIL DRIVES?  // Bandolier;May2007, Vol. 14 Issue 5, p5 

    The article compares Lucentis with Avastin, two sources of anti-vascular endothelial growth factor (VEGF) monoclonal antibodies. It notes that new monoclonal antibodies against VEGF have been shown to reduce choroidal neovascularisation of age-related macular degeneration because VEGF helps...

  • Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. Fraum, Tyler; Kreisl, Teri; Sul, Joohee; Fine, Howard; Iwamoto, Fabio // Journal of Neuro-Oncology;Nov2011, Vol. 105 Issue 2, p281 

    Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), recently received FDA approval for recurrent glioblastoma. Additionally, several VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have entered trials for recurrent glioma. Phase II studies of bevacizumab...

  • Sequential Therapy with Saratin, Bevacizumab and Ilomastat to Prolong Bleb Function following Glaucoma Filtration Surgery in a Rabbit Model. Martorana, Gina M.; Schaefer, Jamie L.; Levine, Monica A.; Lukowski, Zachary L.; Min, Jeff; Meyers, Craig A.; Schultz, Gregory S.; Sherwood, Mark B. // PLoS ONE;9/22/2015, Vol. 10 Issue 9, p1 

    To determine if sequential treatment with Bevacizumab (Avastin), a monoclonal, VEGF antibody that blocks angiogenesis; Saratin, a 12 kD polypeptide with anti-inflammatory and anti-thrombotic properties; and Ilomastat, a matrix metalloproteinase (MMP) inhibitor, prolongs bleb life following...

  • Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review. Rayalam, Srujana; Della-Fera, Mary A.; Kasser, Thomas; Warren, William; Baile, Clifton A. // Recent Patents on Anti-Cancer Drug Discovery;Sep2011, Vol. 6 Issue 3, p367 

    Since tumors cannot grow or spread without forming new blood vessels, inhibiting angiogenesis is an excellent approach for the treatment of cancer. Further, inhibitors of angiogenesis have mild side effects since they act on endothelial cells, which eliminate the possibility of developing...

  • Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens. Yoshida, Noriko; Hisatomi, Toshio; Ikeda, Yasuhiro; Kohno, Ri-ichiro; Murakami, Yusuke; Imaki, Hiroyuki; Ueno, Akifumi; Fujisawa, Kimihiko; Ishibashi, Tatsuro // Graefe's Archive of Clinical & Experimental Ophthalmology;Oct2011, Vol. 249 Issue 10, p1547 

    Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding...

  • Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience. Nieder, Carsten; Wiedenmann, Nicole; Andratschke, Nicolaus H.; Astner, Sabrina T.; Molls, Michael // Reviews on Recent Clinical Trials;Sep2007, Vol. 2 Issue 3, p163 

    Angiogenesis inhibition by monoclonal antibodies against vascular endothelial growth factor receptor (VEGFR) combined with cytotoxic chemotherapy has shown encouraging potential for improvement of cancer treatment. Several rationales exist for combining VEGFR antibodies with ionizing radiation,...

  • Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. Yukari Sekiguchi; Sonoko Misawa; Kazumoto Shibuya; Saiko Nasu; Satsuki Mitsuma; Yuta Iwai; Minako Beppu; Setsu Sawai; Shoichi Ito; Shigeki Hirano; Chiaki Nakaseko; Satoshi Kuwabara // Journal of Neurology, Neurosurgery & Psychiatry;Dec2013, Vol. 84 Issue 12, p1346 

    Objective: Vascular endothelial growth factor (VEGF) plays an essential role in the pathophysiology of polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome. Anti- VEGF antibody (bevacizumab) appears to be an attractive therapeutic option. The aim of this...

  • Bevacizumab in the treatment of high-grade gliomas: an overview. Kunnakkat, Saroj; Narayana, Ashwatha // Angiogenesis;Dec2011, Vol. 14 Issue 4, p423 

    Angiogenesis is a process that is integral to the pathogenesis of high-grade gliomas. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor has emerged as an important therapeutic agent. Data from clinical trials in both recurrent and newly-diagnosed gliomas...

  • Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. Hsu, Jerry Y.; Wakelee, Heather A. // BioDrugs;2009, Vol. 23 Issue 5, p289 

    The use of monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) pathway has been a significant addition to cancer therapy. One of the VEGF family members, VEGF-A (commonly referred to as VEGF), has been demonstrated to be important in angiogenesis. Although the mechanism...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics